CDEK
← All drugs Report issue

sutezolid

Small moleculeexperimental

Sutezolid is an investigational new drug that is being evaluated for the treatment of extensively drug-resistant tuberculosis. It differs from linezolid by replacement of the morpholine oxygen with a sulfur atom. Like linezolid, sutezolid is a bacterial protein synthesis inhibitor. In preclinical studies, sutezolid demonstrated superior antituberculosis activity compared to linezolid. — Wikipedia

Clinical trial activity

9 trials · 23 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
5
Phase 3
1
Phase 4
0

Earliest trial started Apr 1, 2009 (NCT00871949)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)NC[C@H]1CN(c2ccc(N3CCSCC3)c(F)c2)C(=O)O1
Mol. weight
353.42 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • n-((3-(3-fluoro-4-(4-thiomorpholinyl)phenyl)-2-oxo-5-oxazolidinyl)methyl)acetamide
  • pnu-100480
  • pnu-100480
  • pnu-100480
  • pnu-100480
  • sutezolid
  • sutezolid
  • sutezolid
  • sutezolid
  • sutezolid
  • u 100480
  • u-100480
  • u-100480
  • u-100480
  • u-480 compound

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06192160Phase 2Oct 15, 2024National Institute of Allergy and Infectious Diseases (NIAID), TB Alliance, University of California, Berkeley, Vanderbilt University
NCT05686356Phase 2/Phase 3 (Phase 3)Jul 28, 2023Aurum Institute, Global Alliance for TB Drug Development, Government of Mozambique, Katholieke Universiteit Leuven, Ludwig Maximilians University, National Institute for Medical Research, Tanzania, Sequella, Inc., Stellenbosch University, Wits Health Consortium (Pty) Ltd
NCT05971602Phase 2Jul 26, 2023Bill and Melinda Gates Foundation, Global Alliance for TB Drug Development, Janssen Pharmaceutica NV, Otsuka
NCT05807399Phase 2Apr 14, 2023GlaxoSmithKline, LegoChem Biosciences, Inc, Ludwig Maximilians University, Radboud University, University of California, San Francisco, University of London
NCT03959566Phase 2Aug 31, 2019European and Developing Countries Clinical Trials Partnership (EDCTP), German Federal Ministry of Education and Research, Ludwig Maximilians University, Radboud University, Sequella, Inc., University of California, San Francisco
NCT03199313Phase 1Sep 1, 2017Global Alliance for TB Drug Development
NCT01225640Phase 2Aug 1, 2011Sequella, Inc.
NCT00990990Phase 1Oct 1, 2009Sequella, Inc.
NCT00871949Phase 1Apr 1, 2009Sequella, Inc.
Showing 9 of 9 trials
Page 1 / 1

Organizations

Research & Development (23)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Sequella, Inc.For profit5332009
Global Alliance for TB Drug DevelopmentAcademic/Hospital3132017
Ludwig Maximilians UniversityAcademic/Hospital3222019
Radboud UniversityAcademic/Hospital2012019
University of California, San FranciscoAcademic/Hospital2012019
Aurum InstituteAcademic/Hospital1112023
Bill and Melinda Gates FoundationAcademic/Hospital1112023
European and Developing Countries Clinical Trials Partnership (EDCTP)Academic/Hospital1012019
German Federal Ministry of Education and ResearchGovernment1012019
GlaxoSmithKlineFor profit1012023
Government of MozambiqueGovernment1012023
Janssen Pharmaceutica NVFor profit1012023
Katholieke Universiteit LeuvenAcademic/Hospital1012023
LegoChem Biosciences, IncFor profit1012023
National Institute for Medical Research, TanzaniaGovernment1012023
National Institute of Allergy and Infectious Diseases (NIAID)Government1112024
OtsukaFor profit1012023
Stellenbosch UniversityAcademic/Hospital1012023
TB AllianceAcademic/Hospital1012024
University of California, BerkeleyAcademic/Hospital1012024
23 organizations
Page 1 / 2